A conversation with Joseph Tucker, Ph.D., CEO, Enveric Biosciences
Non-hallucinogenic neuroplastogens are being developed as a potentially safer alternative to psychedelics, with a lower risk of hallucinations. Enveric Biosciences is developing a derivative designed to preserve signaling associated with therapeutic neuroplasticity while potentially reducing hallucinogenic risk.
